Hormone receptor mRNA and protein levels as predictors of premenopausal tamoxifen benefit
DOI:
https://doi.org/10.2340/1651-226X.2024.19655Keywords:
breast cancer, tamoxifen, premenopausal patients, randomized trial, estrogen receptor status, progesterone receptor status, predictive informationAbstract
ABSTRACT
Background and purpose: Tamoxifen remains an important adjuvant treatment in premenopausal patients with hormone receptor-positive breast cancer. Thus, determination of hormone receptors is important. Here, we compare cytosol-based methods, immunohistochemistry (IHC), and gene expression (GEX) analysis for determining hormone receptor status in premenopausal breast cancer patients from a randomised tamoxifen trial, to evaluate their performance in identifying patients that benefit from tamoxifen.
Patients and Methods: Premenopausal patients (n=564) were randomised to 2 years of tamoxifen or no systemic treatment. Estrogen receptor (ER) and progesterone receptor (PR) status by protein expression measured by cytosol-based methods and IHC, and mRNA by GEX analysis were compared in 313 patients with available data from all methods. Kaplan Meier estimates and Cox regression were used to evaluate the treatment-predictive value for recurrence-free interval (RFi) and overall survival (OS). Median follow-up for event-free patients was 26 (RFi) and 33 (OS) years.
Results: The mRNA data of ESR1 and PGR distributed bimodally, patterns confirmed in an independent cohort. Kappa-values between all methods were 0.76 and 0.79 for ER and PR, respectively. Tamoxifen improved RFi in patients with ER-positive (ER+) or PR-positive (PR+) tumours (Hazard Ratio [HR] and 95% confidence interval [CI]), cytosol-ER+ 0.53 [0.36–0.79]; IHC-ER+ 0.55 [0.38–0.79]; GEX-ER+ 0.54 [0.37–0.77]; cytosol-PR+ 0.49 [0.34–0.72]; IHC-PR+ 0.58 [0.40–0.85]; GEX-PR+ 0.55 [0.38–0.80]). Results were similar for OS.
Interpretation: These methods can all identify patients that benefit from 2 years of tamoxifen with equal performance, indicating that GEX data might be used to guide adjuvant tamoxifen therapy.
Downloads
References
Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.
https://doi.org/10.1016/S0140-6736(05)66544-0 DOI: https://doi.org/10.1016/S0140-6736(05)66544-0
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–88.
https://doi.org/10.1093/jnci/90.18.1371 DOI: https://doi.org/10.1093/jnci/90.18.1371
Early Breast Cancer Trialists’ Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.
https://doi.org/10.1016/S0140-6736(11)60993-8 DOI: https://doi.org/10.1016/S0140-6736(11)60993-8
Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–95.
https://doi.org/10.1200/JCO.2009.25.6529 DOI: https://doi.org/10.1200/JCO.2009.25.6529
Kim C, Tang G, Pogue-Geile KL, et al. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. J Clin Oncol. 2011;29(31):4160–7.
https://doi.org/10.1200/JCO.2010.32.9615 DOI: https://doi.org/10.1200/JCO.2010.32.9615
Dahlgren M, George AM, Brueffer C, et al. Preexisting somatic mutations of estrogen receptor alpha (ESR1) in early-stage primary breast cancer. JNCI Cancer Spectr. 2021;5(2):pkab028.
https://doi.org/10.1093/jncics/pkab028 DOI: https://doi.org/10.1093/jncics/pkab028
Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(10):1134–50.
https://doi.org/10.1200/JCO.2015.65.2289 DOI: https://doi.org/10.1200/JCO.2015.65.2289
National Institute for Health and Care Excellence (NICE). Early and locally advanced breast cancer: diagnosis and management: version NG101 [Internet]. London: NICE; 2018 [updated 05-04-2023]. Available from: https://www.nice.org.uk/guidance/ng101[cited 20 May 2023]
Curigliano G, Burstein HJ, Gnant M, et al. Understanding breast cancer complexity to improve patient outcomes: the St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann Oncol. 2023;34(11):970–86.
https://doi.org/10.1016/j.annonc.2023.08.017 DOI: https://doi.org/10.1016/j.annonc.2023.08.017
Rydén L, Jönsson PE, Chebil G, et al. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer. 2005;41(2):256–64.
https://doi.org/10.1016/j.ejca.2004.06.030 DOI: https://doi.org/10.1016/j.ejca.2004.06.030
Ekholm M, Bendahl PO, Ferno M, Nordenskjold B, Stal O, Ryden L. Two years of adjuvant tamoxifen provides a survival benefit compared with no systemic treatment in premenopausal patients with primary breast cancer: long-term follow-up (> 25 years) of the Phase III SBII:2pre trial. J Clin Oncol. 2016;34(19):2232–8.
https://doi.org/10.1200/JCO.2015.65.6272 DOI: https://doi.org/10.1200/JCO.2015.65.6272
Ekholm M, Bendahl PO, Ferno M, et al. Effects of adjuvant tamoxifen over three decades on breast cancer-free and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial. Eur J Cancer. 2019;110:53–61.
https://doi.org/10.1016/j.ejca.2018.12.034 DOI: https://doi.org/10.1016/j.ejca.2018.12.034
Lundgren C, Bendahl PO, Ekholm M, et al. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up. Breast Cancer Res. 2020;22(1):140.
https://doi.org/10.1186/s13058-020-01364-w DOI: https://doi.org/10.1186/s13058-020-01364-w
Larsson A-M, Jansson S, Bendahl P-O, et al. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Breast Cancer Res. 2018;20(1):48.
https://doi.org/10.1186/s13058-018-0976-0 DOI: https://doi.org/10.1186/s13058-018-0976-0
Jørgensen CLT, Larsson AM, Forsare C, et al. PAM50 intrinsic subtype profiles in primary and metastatic breast cancer show a significant shift toward more aggressive subtypes with prognostic implications. Cancers (Basel). 2021;13(7):1592.
https://doi.org/10.3390/cancers13071592 DOI: https://doi.org/10.3390/cancers13071592
Lundgren C, Bendahl PO, Church SE, et al. PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients. NPJ Breast Cancer. 2022;8(1):61.
https://doi.org/10.1038/s41523-022-00423-z DOI: https://doi.org/10.1038/s41523-022-00423-z
Fernö M, Borg A, Johansson U. Enzyme immunoassay of progesterone receptor in breast cancer biopsy samples. A comparison with the dextran coated charcoal method. Acta Oncol. 1989;28(1):19–22.
https://doi.org/10.3109/02841868909111175 DOI: https://doi.org/10.3109/02841868909111175
Fernö M, Borg å, Sellberg G. Enzyme immuno assay of the estrogen receptor in breast cancer biopsy samples a comparison with isoelectric focusing. Acta Radiol Oncol. 1986;25(3):171–5.
https://doi.org/10.3109/02841868609136398 DOI: https://doi.org/10.3109/02841868609136398
NanoString Technologies. nCounter® Breast Cancer 360™ Panel [Internet]. Seattle: Nanostring Technologies; 2023 [cited 17-02-2023]. Available from: https://nanostring.com/products/ncounter-assays-panels/oncology/breast-cancer-360/
Leeflang MM, Moons KG, Reitsma JB, Zwinderman AH. Bias in sensitivity and specificity caused by data-driven selection of optimal cutoff values: mechanisms, magnitude, and solutions. Clin Chem. 2008;54(4):729–37.
https://doi.org/10.1373/clinchem.2007.096032 DOI: https://doi.org/10.1373/clinchem.2007.096032
Gourgou-Bourgade S, Cameron D, Poortmans P, et al. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). Ann Oncol. 2015;26(5):873–9.
https://doi.org/10.1093/annonc/mdv106 DOI: https://doi.org/10.1093/annonc/mdv106
Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med. 2012;10:51.
https://doi.org/10.1186/1741-7015-10-51 DOI: https://doi.org/10.1186/1741-7015-10-51
Wigertz A, Ahlgren J, Holmqvist M, et al. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat. 2012;133(1):367–73.
https://doi.org/10.1007/s10549-012-1961-4 DOI: https://doi.org/10.1007/s10549-012-1961-4
Khoshnoud MR, Löfdahl B, Fohlin H, et al. Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen. Breast Cancer Res Treat. 2011;126(2):421–30.
https://doi.org/10.1007/s10549-010-1202-7 DOI: https://doi.org/10.1007/s10549-010-1202-7
Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004;17(12):1545–54.
https://doi.org/10.1038/modpathol.3800229 DOI: https://doi.org/10.1038/modpathol.3800229
Molino A, Micciolo R, Turazza M, et al. Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat. 1997;45(3):241–9.
https://doi.org/10.1023/A:1005769925670 DOI: https://doi.org/10.1023/A:1005769925670
Badve SS, Baehner FL, Gray RP, et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol. 2008;26(15):2473–81.
https://doi.org/10.1200/JCO.2007.13.6424 DOI: https://doi.org/10.1200/JCO.2007.13.6424
Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21(10):1973–9.
https://doi.org/10.1200/JCO.2003.09.099 DOI: https://doi.org/10.1200/JCO.2003.09.099
Stendahl M, Rydén L, Nordenskjöld B, Jönsson PE, Landberg G, Jirström K. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res. 2006;12(15):4614–8.
https://doi.org/10.1158/1078-0432.CCR-06-0248 DOI: https://doi.org/10.1158/1078-0432.CCR-06-0248
Nordenskjöld A, Fohlin H, Fornander T, Löfdahl B, Skoog L, Stål O. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2016;160(2):313–22.
https://doi.org/10.1007/s10549-016-4007-5 DOI: https://doi.org/10.1007/s10549-016-4007-5
Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019;37(5):423–38.
https://doi.org/10.1200/JCO.18.01160 DOI: https://doi.org/10.1200/JCO.18.01160
Partridge AH, Niman SM, Ruggeri M, et al. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med. 2023;388(18):1645–56.
https://doi.org/10.1056/NEJMoa2212856 DOI: https://doi.org/10.1056/NEJMoa2212856
Ji P, Gong Y, Jin ML, Hu X, Di GH, Shao ZM. The burden and trends of breast cancer From 1990 to 2017 at the global, regional, and national levels: results from the global burden of disease study 2017. Front Oncol. 2020;10:650.
https://doi.org/10.3389/fonc.2020.00650 DOI: https://doi.org/10.3389/fonc.2020.00650
Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–26.
https://doi.org/10.1056/NEJMoa041588 DOI: https://doi.org/10.1056/NEJMoa041588
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Terese Engström, Maria Ekholm, Mårten Fernö, Christine Lundgren, Bo Nordenskjöld, Olle Stål, Pär-Ola Bendahl, Julia Tutzauer, Lisa Rydén
This work is licensed under a Creative Commons Attribution 4.0 International License.
